...
首页> 外文期刊>American Journal of Physiology >Transcriptional regulation of SP-B gene expression by nitric oxide in H441 lung epithelial cells.
【24h】

Transcriptional regulation of SP-B gene expression by nitric oxide in H441 lung epithelial cells.

机译:一氧化氮对H441肺上皮细胞中SP-B基因表达的转录调控。

获取原文
获取原文并翻译 | 示例

摘要

Surfactant protein B (SP-B) is essential for the surface tension-lowering function of pulmonary surfactant. Surfactant dysfunction and reduced SP-B levels are associated with elevated nitric oxide (NO) in inflammatory lung diseases, such as acute respiratory distress syndrome. We previously found that NO donors decreased SP-B expression in H441 and MLE-12 lung epithelial cells by reducing SP-B promoter activity. In this study, we determined the roles of DNA elements and interacting transcription factors necessary for NO inhibition of SP-B promoter activity in H441 cells. We found that the NO donor diethylenetriamine-nitric oxide adduct (DETA-NO) decreased SP-B promoter thyroid transcription factor 1 (TTF-1), hepatocyte nuclear factor 3 (HNF-3), and Sp1 binding activities but increased activator protein 1 (AP-1) binding activity. DETA-NO decreased TTF-1, but not Sp1, levels, suggesting that reduced TTF-1 expression contributes to reduced TTF-1 binding activity. Lack of effect on Sp1 levels suggested that DETA-NO inhibits Sp1 binding activity per se. Overexpression of Sp1, but not TTF-1, blocked DETA-NO inhibition of SP-B promoter activity. DETA-NO inhibited SP-B promoter induction by exogenous TTF-1 without altering TTF-1 levels. DETA-NO decreased TTF-1 mRNA levels and gene transcription rate, indicating that DETA-NO inhibits TTF-1 expression at the transcriptional level. We conclude that NO inhibits SP-B promoter by decreasing TTF-1, Sp1, and HNF-3 binding activities and increasing AP-1 binding activity. NO inhibits TTF-1 levels and activity to decrease SP-B expression. NO inhibition of SP-B expression could be a mechanism by which surfactant dysfunction occurs in inflammatory lung diseases.
机译:表面活性剂蛋白B(SP-B)对于肺表面活性剂的表面张力降低功能至关重要。在炎症性肺病(例如急性呼吸窘迫综合征)中,表面活性剂功能障碍和SP-B水平降低与一氧化氮(NO)升高有关。我们以前发现NO供体通过降低SP-B启动子活性来降低H441和MLE-12肺上皮细胞中SP-B的表达。在这项研究中,我们确定了NO抑制H441细胞中SP-B启动子活性所必需的DNA元件和相互作用的转录因子的作用。我们发现,NO供体二亚乙基三胺一氧化氮加合物(DETA-NO)降低SP-B启动子甲状腺转录因子1(TTF-1),肝细胞核因子3(HNF-3)和Sp1结合活性,但增加激活蛋白1 (AP-1)结合活性。 DETA-NO降低了TTF-1的水平,但不降低Sp1的水平,这表明降低的TTF-1表达有助于降低的TTF-1结合活性。对Sp1水平的影响不足表明DETA-NO本身抑制了Sp1的结合活性。 Sp1而不是TTF-1的过表达阻止了DETA-NO对SP-B启动子活性的抑制。 DETA-NO抑制外源TTF-1诱导SP-B启动子,而不会改变TTF-1水平。 DETA-NO降低TTF-1 mRNA水平和基因转录速率,表明DETA-NO在转录水平上抑制TTF-1表达。我们得出结论,NO通过降低TTF-1,Sp1和HNF-3结合活性并增加AP-1结合活性来抑制SP-B启动子。 NO抑制TTF-1的水平和抑制SP-B表达的活性。 NO抑制SP-B的表达可能是炎症性肺疾病中表面活性剂功能异常的机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号